FRANKFURT, July 25 (Reuters) - Roche's CEO said

the Swiss company is looking into potentially acquiring further

obesity drug development assets even after the $2.7 billion

Carmot Therapeutics takeover, agreed in December.

Speaking in a media call after the release of first-half

results, CEO Thomas Schinecker also said that 25% of projects in

the group's drug development pipeline had been stopped over the

last 12 months to shift resources to the most promising

projects. He took the helm in March 2023.